Strategies To Slow Generic Drug Entries Include Early Patent Activity
This article was originally published in The Tan Sheet
Executive Summary
Brand name manufacturers' early announcements of patent activity may deter generic companies as they consider opportunities and risks prior to patent expirations, A.T. Kearney VP-Pharmaceutical Practice Richard Findlay told a Food & Drug Law Institute conference on the Waxman/Hatch Act Nov. 23.